Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging of Solid Tumors Using FAP-2286
NCT04621435Phase 1Recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-FAP-2286 and 64Cu-FAP-2286 in solid tumor (4 cohorts). Primary endpoints: Count of participants with treatment-emergent adverse events at 1 day, Proportion of radiation-absorbed doses of radiolabeled FAP-2286 up to 3 days and 3 more. Started Dec 2020; status: recruiting.
02
Drugs
68Ga-FAP-228664Cu-FAP-2286
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04621435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621435.